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Hepatic steatosis is a major risk factor in ischemia-reperfusion (I/R). IGF-binding proteins (IGFBPs)
modulate IGF-I actionby transportingcirculating IGF-I to its sitesofaction. Epidermalgrowth factor
(EGF) stimulates IGF-I synthesis in vitro. We examined the effect of IGF-I and EGF treatment,
separatelyor in combination, on thevulnerabilityof steatotic livers to I/R.Our results indicated that
I/R impaired IGF-I synthesis only in steatotic livers. Only when a high dose of IGF-I (400 g/kg) was
given to obese animals did they show high circulating IGF-I:IGFBP levels, increased hepatic IGF-I
levels, and protection against damage. In lean animals, a dose of 100 g/kg IGF-I protected non-
steatotic livers. Our results indicated that the combined administration of IGF-I and EGF resulted
in hepatic injury parameters in both liver types similar to that obtainedby IGF-I and EGF separately.
IGF-I increasedegfexpression inboth liver types. Thebeneficial roleofEGFonhepatic I/R injurymay
be attributable to p38 inhibition in nonsteatotic livers and to PPAR overexpression in steatotic
livers. In conclusion, IGF-I and EGF may constitute new pharmacological strategies to reduce the
inherent susceptibility of steatotic livers to I/R injury. (Endocrinology 150: 3153–3161, 2009)
Hepatic steatosis is a major risk factor after liver surgerybecause steatotic livers show poor tolerance to ischemia-
reperfusion (I/R) (1). Operative mortality associated with ste-
atosis exceeds 14% after major resection comparedwith 2% for
healthy livers (2, 3). In the caseof transplantation, steatotic grafts
are associated with a primary nonfunction rate of 60% com-
paredwith less than 5% for nonsteatotic grafts (4, 5). Therefore,
developing protective strategies to minimize the adverse effects
of I/R injury in steatotic livers is an urgent need.
IGF-I is member of the IGF superfamily and participates in
numerous pathophysiological processes (6–9). The IGF-bind-
ing proteins (IGFBPs), which are abundant in the blood-
stream, organs, and tissues act as major modulators of IGF-I
action by transporting IGF-I to its sites of action (7, 10, 11).
Interaction between growth factor families is a field of grow-
ing interest. Various in vitro studies indicate that epidermal
growth factor (EGF) stimulates IGF-I synthesis in renal cells
and isolated hepatocytes (12–14).
To our knowledge, the beneficial effects of IGF-I on hepatic
I/R injury have been reported only in nonsteatotic livers (15),
whereas the effects of EGF on hepatic I/R injury remain un-
known. The first purpose of this study was to evaluate whether
treatment with IGF-I and EGF could improve the poor tolerance
of steatotic livers to I/R.Given thatEGFenhances igf1 expression
in several cell types (12–14), the secondpurpose of this studywas
to evaluate whether EGF provides a stimulus for igf1 expression
in hepatic I/R. Finally, the third purpose of the present studywas
to evaluate the involvement of p38MAPK (p38) andperoxisome
proliferator-activated receptor- (PPAR) in the effects of IGF-I
andEGFonhepatic I/R injury in steatotic andnonsteatotic livers.
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This approach was based on 1) previous studies from our group
revealing thekey role of bothp38andPPAR in nonsteatotic and
steatotic livers, respectively, under I/R conditions (16, 17) and 2)
data reported in the literature indicating that IGF-I and EGF
affect p38 and PPAR in several different conditions (18–21).
Our findings could lead to the design of new pharmacological
strategies in liver surgery for reducing hepatic I/R injury.
Materials and Methods
Experimental animals
Homozygous (obese, Ob) and heterozygous (lean, Ln) Zucker rats
(Iffa-Credo, Lábresle, France) aged16–18wkwere used.ObZucker rats
have a mutated leptin receptor and, as a consequence, are hyperphagic,
obese, and hyperinsulinemic, because they are insulin resistant, but have
normal blood glucose levels. ObZucker rats do not develop diabetes. Ln
Zucker rats maintain a lean phenotype throughout life, with normal
blood insulin and glucose levels (22, 23). Control experiments from our
group confirmed that none of the drugs included in the present study
altered the plasma insulin or glucose levels inObZucker rats.ObZucker
rats showed severe macrovesicular and microvesicular fatty infiltration
in hepatocytes (60–70% steatosis). Ln Zucker rats showed no evidence
of steatosis. The animals were anesthetized with ketamine and xylazine
(100 and 8 mg/kg, respectively) (17). The study followed European
Union regulations (ECC Directive 86/609) governing animal
experiments.
Experimental design
All animals were randomly sorted into groups.
Protocol 1: effects of IGF-I and EGF administration on
hepatic I/R
Animals were divided into five groups: 1) sham (n  12, six Ln and
six Ob), in which hepatic hilium vessels were dissected; I/R (n 12, six
Ln and six Ob), in which 60 min partial (70%) hepatic ischemia was
followed by 24 h reperfusion (17); 3) subgroup 3.1, IGF-I (100) (n 12,
six Ln and six Ob), same as group 2 but treated with IGF-I at doses of 100
g/kg (every 12 h for two doses, starting immediately before surgical pro-
cedure) (24, 25), and subgroup 3.2, IGF-I (400) (n 6Ob), same as group
2 but treated with IGF-I at doses of 400 g/kg (every 12 h for two doses,
starting immediatelybefore surgicalprocedure) (24,25);4)EGF(n12, six
Lnand sixOb), sameas group2but treatedwithEGFat doses of 100g/kg
(every 8 h for three doses, starting immediately before surgical procedure)
(26); and 5) IGF-IEGF (n 12, six Ln and six Ob), same as group 2 but
treatedwith IGF-Iatdosesof100g/kg inLnand400g/kg inObandEGF
at doses of 100g/kg for Ln andOb. The pretreatment times for IGF-I and
EGF were as described above (24–26).
Preliminary studies from our group based on dose response demon-
strated that the doses of IGF-I (100 g/kg for Ln and 400 g/kg for Ob)
and EGF (100g/kg for Ln andOb)were themost effective in protecting
the two liver types against I/R damage.
Protocol2: roleofp38intheeffectsofEGFonhepatic I/R injury
Animals were divided into three additional groups: 6) p38 inhibitor (n
6 Ln), same as group 2 but treated with SB203580, a p38 inhibitor, at a
doseof 1mg/kg24hbefore surgical procedure (27); 7) p38activator (n
6 Ln), same as group 2 but treated with anisomycin, a p38 activator, at
adoseof 0.1mg/kg24hbefore surgical procedure (27); and8)EGFp38
activator (n  6 Ln), same as group 2 but treated with EGF at doses of
100 g/kg and anisomycin, a p38 activator, at a dose of 0.1 mg/kg 24 h
before surgical procedure (27). The pretreatment times for EGF were as
described above (26).
Protocol 3: role of PPAR in the effects of EGF onhepatic I/R
injury
Again, animals were divided into three additional groups: 9) PPAR
antagonist (n  6 Ob), same as group 2 but treated with GW9662, a
PPAR antagonist, at a dose of 1 mg/kg before surgical procedure (17);
10) PPAR agonist (n  6 Ob), same as group 2 but treated with ros-
iglitazone, a PPAR agonist, at a dose of 1.5 mg/kg before and after
surgical procedure (17); and 11) EGFPPAR antagonist (n  6 Ob),
same as group 2 but treated with EGF at a dose of 100 g/kg and
GW9662, a PPAR antagonist, at a dose of 1 mg/kg before surgical
procedure (17). The pretreatment times for EGFwere as described above (26).
Plasma and liver samples were collected after hepatic reperfusion.
Quantitative RT-PCR
Quantitative real-time PCR analysis was performed by the premade
Assays-on-Demand TaqMan probes (Rn00710306_m1 for igf1,
Rn00563336_m1 for egf, and Rn00667869_m1 for -actin) (Applied Bio-
systems, Foster City, CA). The TaqMan gene expression assay was per-
formed according to the manufacturer’s protocol (Applied Biosystems).
Western blotting of IGF-I, EGF, IGFBP-3, p38, PPAR, and
-actin
Western blotting was performed as described elsewhere (16, 17),
using the following antibodies: IGF-I, EGF, and IGFBP-3 (Santa Cruz
Biotechnology, Santa Cruz, CA) total p38 and phosphorylated p38 (Cell
Signaling Technology Inc., Beverly, MA), PPAR- (Abcam, UK), and
-ActIn (Sigma Chemical Co., St. Louis, MO).
Biochemical determinations
Transaminases were evaluated according to standard procedures.
The concentration of total IGF-I in plasmawas determined by amodified
acid-ethanol (0.25 N HCl/87.5% ethanol) procedure with cryoprecipi-
tation. Then, total IGF-I in plasma was determined by ELISA kit from
Immunodiagnostic Systems (Fountain Hills, AZ) according to the man-
ufacturer’s instructions. The plasma concentration of free IGF-I was
determined by centrifugal ultrafiltration. Briefly, the plasma samples
were diluted 1:5withKrebs-Ringer bicarbonate buffer (pH7.4,with 5%
BSA) and prefiltered through a 0.22-m filter (Millex-GV; Millipore,
Molsheim, France) to remove debris. The prefiltered samples were then
added to Amicon YMT 30 membranes and MPS-1 supporting devices
(Amicon Division, W. R. Grace, Beverly, MA) and centrifuged at 300
g at 37 C for 100 min. The ultrafiltrate was collected from 40–100 min
centrifugation and used for the determination of IGF-I by an ELISA kit
from Immunodiagnostic Systems following manufacturer’s guidelines
(28, 29). IGFBP-3 levels in plasma were determined by using an ELISA
kit from Diagnostic Systems Laboratories (Webster, TX), according to
manufacturer’s instructions (30).
Histology and red-oil staining
Hematoxylin- and eosin-stained sections were evaluated as follows:
grade 0,minimal or no evidence of injury; grade 1,mild injury consisting
of cytoplasmic vacuolation and focal nuclear pyknosis; grade 2, mod-
erate to severe injury with extensive nuclear pyknosis, cytoplasmic hy-
pereosinophilia, and loss of intercellular borders; and grade 3, severe
necrosis with disintegration of hepatic cords, hemorrhage, and neutro-
phil infiltration (31, 32). Steatosis in liver was evaluated by red-oil stain-
ing on frozen specimens, according to standard procedures.
Statistics
Data are expressed as means SE andwere compared statistically by
ANOVA, followed by Student-Newman-Keuls test. P  0.05 was con-
sidered significant.
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Results
Effect of I/R on hepatic and circulating IGF-I
In Ln animals, I/R resulted in hepatic igf1 mRNA and IGF-I
protein levels that were similar to those of the sham group (Fig.
1A). However, in Ob animals, I/R reduced hepatic igf1 mRNA
and IGF-I protein levels when compared with the sham group
(Fig. 1A). Circulating IGF-I is mainly derived from the liver (33,
34). Our results indicated that IGF-I levels in plasma (Fig. 1B)
showed a similar pattern to IGF-I observed in the liver (Fig. 1A).
Effects of IGF-I administration on hepatic I/R
In Ln animals, I/R resulted in total and free IGF-I in plasma
that was similar to that in the sham group (Fig. 2A). In Ob
animals, I/R reduced total and free IGF-I levels in plasma when
compared with the sham group. IGF-I administration in Ln and
Ob animals increased total and free plasma IGF-I levels when
compared with the I/R group (Fig. 2A). IGFBPs act as major
modulators of IGF-I action by transporting circulating IGF-I to
their sites of action (7, 10, 11). In Ln animals, I/R resulted in a
percentage of IGF-I bound to IGFBPs (IGF-I:IGFBP complex) in
plasma that was similar to that in the sham group (Fig. 2A). In
Ob animals, I/R reduced IGF-I:IGFBP complex in plasma when
compared with the sham group (Fig. 2A). As previously men-
tioned, in Ob animals, I/R reduced hepatic IGF-I protein levels
when compared with the sham group (Fig. 2B). Transaminase
and damage score values of the I/R groupwere higher in steatotic
livers than in nonsteatotic livers (Fig. 2C), indicating that stea-
totic livers are more vulnerable to hepatic I/R damage. The ad-
ministration of IGF (100 g/kg) in Ln animals increased the
IGF-I:IGFBP complex in plasma comparedwith the I/R group or
the sham group (Fig. 2A). This was associated with increased
hepatic IGF-I levels (Fig. 2B) and reduced hepatic injury (Fig.
2C). At the same dose (100 g/kg), IGF-I administration in Ob
animals increased IGF-I:IGFBP complex in plasma over that re-
corded in the I/R group, although levels were similar to those of
the sham group (Fig. 2A). This was not associatedwith increases
in hepatic IGF-I levels (Fig. 2B) or protection against hepatic
damage (Fig. 2C) when compared with the I/R group. However,
the administration of IGF-I (400 g/kg) in Ob animals resulted
in a marked increase in circulating IGF-I:IGFBP levels (Fig. 2A),
which was associated with increased hepatic IGF-I levels (Fig.
2B) and reduced hepatic injury (Fig. 2C).
Effect of IGF-I on circulating and hepatic IGFBP-3
IGFBP-3 binds themajority of circulating IGF-I (90%) (33, 35).
In both Ln and Ob animals, I/R led to circulating IGFBP-3
levels similar to those of the sham group (Fig. 3A). The admin-
istration of IGF-I at the effective dose (100 and 400 g/kg in Ln
and Ob animals, respectively) reduced IGFBP-3 in plasma when
comparedwith the I/R group. In both Ln andObanimals, I/R led
to hepatic IGFBP-3 levels similar to those of the shamgroup (Fig.
3A). IGF-I administration at the effective dose in bothLn andOb
animals increased hepatic IGFBP-3 protein levels when com-
paredwith the I/Rgroup (Fig. 3A)butdidnot alter hepatic igfbp3
mRNA levels. Thus, the igfbp3 values (expressed as x-fold
mRNA induction) in nonsteatotic livers were 0.89  0.24 and
0.88  0.25 for I/R and IGF-I groups, respectively. The igfbp3
values in steatotic livers were 0.80  0.32 and 0.87  0.34 for
I/R and IGF-I groups, respectively.
Effect of IGF-I on hepatic EGF
PretreatmentwithEGF (at the samedose, 100g/kg inLnand
Ob) reduced hepatic injury in both liver types when compared
with the I/R group (Fig. 3B). The combined administration of
IGF-I (at the effective dose, 100 and 400 g/kg in Ln and Ob,
respectively) and EGF (100 g/kg in Ln and Ob) resulted in
similar hepatic injury parameters in both liver types to those
obtained by IGF-I and EGF administration, separately (Fig. 3B).
EGF administration in both Ln and Ob animals did not alter
hepatic IGF-I, because the igf1 mRNA and IGF-I protein levels
FIG. 1. A, igf1 mRNA expression and IGF-I protein levels in liver. For igf1 mRNA
expression in liver, PCR fluorescent signals for IGF-I were standardized to PCR
fluorescent signals obtained from an endogenous reference (-actin).
Comparative and relative quantifications of igf1 gene products normalized to
-actin and control sham group were calculated by the 2CT method. For IGF-I
protein levels in liver, representative Western blot (top) and densitometric analysis
(bottom) were performed. B, IGF-I protein levels in plasma. *, P  0.05 vs. sham.
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observed in both liver types after EGF treatment were similar to
those of the I/R group (Fig. 4A). However, IGF-I administration
in both Ln and Ob animals (at the effective dose, 100 and 400
g/kg in Ln and Ob, respectively) increased hepatic egf mRNA
expression and EGF-I protein levels over those of the I/R group
(Fig. 4B).
Protective mechanisms of EGF in hepatic I/R
I/R increased phosphorylated p38 levels in both type of livers
when compared with the sham group (Fig. 5A). The protein
levels of total p38 were unchanged in all groups. EGF adminis-
tration in Ln animals reduced hepatic phosphorylated p38 levels
when compared with the I/R group. However, EGF administra-
tion inOb animals resulted in hepatic phosphorylated p38 levels
similar to those of the I/R group (Fig. 5A). The effect of EGF on
PPAR in the presence of steatosis was also evaluated. As pre-
viously reported (17), I/R induced changes in PPAR levels only
in steatotic livers (Fig. 5A). EGF administration in Ob animals
increased PPAR levels when compared with the I/R group. No
changes in PPAR were observed in nonsteatotic liver of any
group comparedwith the sham group (Fig. 5A). Like EGF, IGF-I
also reduced p38 levels in nonsteatotic livers and increased
PPAR levels in steatotic livers when compared with the I/R
group (data not shown). This may be due to the fact that IGF-I
increased EGF.
Next, the relevance of the changes in p38 and PPAR induced
by EGF treatment in nonsteatotic and steatotic livers, respec-
tively, was also evaluated. First we showed that the increase in
p38 induced by I/R had injurious effects on hepatic damage in
nonsteatotic livers. Administration of p38 inhibitor in Ln ani-
mals reduced hepatic injury when compared with the I/R group
(Fig. 5B). To test our hypothesis (that EGF exerts its action in
nonsteatotic livers through p38 inhibition), we used a p38 acti-
vator at adose that increasedp38 levels to the same levels as those
of the I/R group but not higher. We carried out control experi-
ments to confirm that in all groups treated with p38 activator,
FIG. 2. A, Total IGF-I, free IGF-I, and IGF-I:IGFBP complexes in plasma. B, IGF-I protein levels in liver. Representative Western blot (top) and densitometric analysis
(bottom) are shown. C, Hepatic injury (Alanine Aminotransferase levels and damage score). *, P  0.05 vs. sham; , P  0.05 vs. I/R. Transaminase levels and damage
score are significantly higher in the untreated Ob group than in the untreated Ln group (#, P  0.05).
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p38 levels were similar to those of the I/R group (data not
shown). Thus, the administration of p38 activator in Ln animals
(p38 activator group) resulted in similar hepatic p38 levels to
those of the I/R group (data not shown) and, consequently, sim-
ilar parameters of hepatic injury to those of the I/R group (Fig.
5B).As previouslymentioned, EGFadministration inLnanimals
(EGF group) reduced hepatic phosphorylated p38 levels with
respect to thoseof the I/Rgroup (Fig. 5A), and thiswasassociated
with reduced hepatic injury (Fig. 5B). However, the administra-
tion of both EGF and p38 activator in Ln animals (EGFp38
group) resulted in hepatic p38 levels similar to those of the I/R
group (data not shown), and this was associated with biochem-
ical and histological parameters of hepatic injury that were sim-
ilar to those of the I/R group (Fig. 5B). Thus, when p38 activator
was administered, EGF pretreatment did not protect nonstea-
totic livers against hepatic I/R injury.
Regarding PPAR, the slight but significant increase in
PPAR levels that occurred in steatotic livers as a consequence of
I/R (Fig. 5A) had no effect on hepatic injury, because the admin-
istration of PPAR antagonist inOb animals (PPAR antagonist
group) resulted in hepatic injury parameters that were similar to
those of the I/R group (Fig. 5B). Previous studies (17) reported
that PPAR agonist pretreatment or strategies that increase
PPAR levels over those found in I/R protect steatotic livers
against hepatic I/R injury. PPAR agonist administration in Ob
animals (PPAR agonist group) reduced hepatic injury when
compared with the I/R group (Fig. 5B). As shown above, EGF
administration in Ob animals (EGF group) increased hepatic
PPAR levels in steatotic livers over those found in the I/R group
(Fig. 5A), and this was associated with reduced hepatic injury
(Fig. 5B). The administration of both EGF and PPAR antago-
nist in Ob animals (EGF PPAR antagonist group) resulted in
hepatic injury parameters that were similar to those of the I/R
group despite the presence of EGF (Fig. 5B).
Discussion
Hepatic synthesis and secretion of IGF-I is impaired in inflam-
matory conditions such as sepsis, endotoxemia, and cirrhosis
(36–38). Our results, based on hepatic igf1 mRNA and IGF-I
protein levels, indicate that synthesis of IGF-I is impaired in stea-
totic livers of Ob animals subjected to I/R. The decrease in cir-
culating IGF-I observed in various liver disorders could result
FIG. 3. A, IGFBP-3 protein levels in liver and plasma. For IGFBP-3 protein levels in liver, representative Western blot (top) and densitometric analysis (bottom) were
performed. B, Effect of IGF-I and EGF administration on hepatic injury (alanine aminotransferase levels and damage score). *, P  0.05 vs. sham; , P  0.05 vs. I/R.
Transaminase levels and damage score are significantly higher in the untreated Ob group than in the untreated Ln group (#, P  0.05). There were no significant
differences in the hepatic injury parameters between IGF-I, EGF, and EGFIGF groups.
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from a decrease in the rate of synthesis and an increase in the rate
of removal from the blood (28, 37). The correlation between
hepatic and circulating IGF-I indicates that the reduction in cir-
culating IGF-I levels observed inOb animals subjected to hepatic
I/R could mainly be due to hepatic IGF-I synthesis reduction.
Nevertheless, an increase in the rate of removal from the blood
should not be ruled out.
The causes of the decrease in IGF-I synthesis observed in stea-
totic livers undergoing I/Rwere not explored in this study.How-
ever, a failure in the GH signaling pathway in steatotic livers
under I/Rconditions shouldnotbe ruledout.GHis released from
the anterior pituitary gland, binds to its receptors in the liver, and
thus, in turn synthesizes IGF-I (38). A decrease in GH secretion
and alterations in the number of GH receptors have been ob-
served in liver disorders caused by alcohol consumption, thermal
injury, or Laron’s syndrome. This leads to GH resistance in the
liver, with a corresponding reduction in hepatic IGF-I synthesis
(28, 39, 40).
We show here that in contrast to Ln animals, IGF-I admin-
istration at the dose of 100 g/kg in Ob animals was not asso-
ciated with either an increase in hepatic IGF-I protein levels or
protection against damage. Thus, a higher dose of IGF-I had to
be administered in Ob animals to protect steatotic livers effec-
tively. This could be explained, at least partially, by the impair-
ment of IGF-I synthesis induced by I/R in steatotic livers.
IGFBP-3 bindsmost circulating IGF-I (41), but a smaller pro-
portion of IGF-I is associated with other serum IGFBPs (IG-
FBP-1, -2, -4, -5, and -6) (42, 43). Surprisingly, this did not
appear to occur in the conditions of the present study. According
to our results, in plasma of the shamOb group, total IGF-I levels
were about 200 nM, IGFBP-3 levels were about 30 nM, and the
percentage of IGF-I bound to IGFBPs was about 50%. Consid-
ering that one molecule of IGF-I binds one molecule of IGFBP-3
(44, 45), this indicates that another IGFBP apart from IGFBP-3
must be present at unusually high concentration for 50% of
IGF-I to be in complexes. Similarly, in plasma of Ob rats under-
going I/R and treated with IGF-I at the effective dose, total IGF-I
levels were about 640 nM, IGFBP-3 levels were about 15 nM, and
the percentage of IGF-I bound to IGFBPs was 80%. This indi-
cates that another IGFBP apart from IGFBP-3must be present at
unusually high concentration for 80% of IGF-I to be in com-
plexes. Thus, further research will be needed to identify the IG-
FIG. 4. A, Effect of EGF administration on igf1 mRNA expression and IGF-I protein levels in liver. B, Effect of IGF-I administration on egf mRNA expression and EGF
protein levels in liver. For igf1 and egf mRNA expression in liver, PCR fluorescent signals for IGF-I and EGF were standardized to PCR fluorescent signals obtained from
an endogenous reference (-actin). Comparative and relative quantifications of igf1 and egf gene products normalized to -actin and control sham group were
calculated by the 2CT method. For IGF-I and EGF protein levels in liver, representative Western blot (top) and densitometric analysis (bottom) were performed.
*, P  0.05 vs. sham; , P  0.05 vs. I/R.
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FBPs other than IGFBP-3 that should be considered under warm
hepatic I/R conditions in both liver types.
In addition to acting as a binding protein of circulating IGF-I,
IGFBP-3 has been reported to have IGF-I-independent actions;
IGFBP-3 inhibits cellular proliferation and enhances apoptosis
by binding to the cell membrane (46–49). These effects of IG-
FBP-3 are injurious in conditions of hepatic I/R. Because our
results showed that increases in hepatic IGFBP-3were in parallel
with hepatic protection, it seems unlikely that in the conditions
evaluated herein, IGFBP-3 has IGF-independent effects. Further
studies will be required to clarify why IGF-I administration in-
creased hepatic IGF-I protein levels but reduced plasma IGFBP-3
levels, considering that IGF-I is one of the main positive regula-
tors of IGFBP-3 levels (50, 51). Nevertheless, on the basis of
previous reports in other pathologies, we hypothesize that a de-
crease in circulating IGFBP-3 could be explained, at least par-
FIG. 5. A, Effect of EGF administration on phosphorylated p38 (Pp38) protein levels and PPAR protein levels in liver. Representative Western blot (top) and
densitometric analysis (bottom) are shown. B, Hepatic injury (alanine aminotransferase levels and damage score) after pharmacological modulation of p38 in
nonsteatotic livers and PPAR in steatotic livers. *, P  0.05 vs. sham; , P  0.05 vs. I/R.
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tially, by increased IGFBP-3 rate of clearance or enhanced IG-
FBP-3 proteolysis (41, 52).
It should be considered that IGF-I and EGF decrease hepatic
I/R injury but do not preserve the liver from I/R injury. The latter
is a complex process in which several mechanisms participate
(53) but not all of which are affected by EGF and IGF-I. The
ability of IGF-I and EGF to protect both liver types against I/R
injury is of particular interest because numerous strategies that
are effective in nonsteatotic livers may not be useful in the pres-
ence of steatosis (31, 53). It should be noted that the adminis-
tration of EGF resulted in hepatic injury parameters similar to
those obtained by IGF. However, EGF seems to be the most
appropriate therapeutic strategy. Our main argument is that the
IGF-I dose that protected against I/R injury is different for stea-
totic and nonsteatotic livers. This may be an obstacle to its ther-
apeutic use in clinical practice. Moreover, it would appear to be
more reasonable to administer the ultimate effecter of the cas-
cade, EGF in this case, because its effects are more direct.
Hereinwe showed that the combined administration of IGF-I
and EGF resulted in hepatic injury parameters in both liver types
that were similar to those induced by IGF-I and EGF separately.
Thus, a combination of IGF-I and EGF seems unnecessary to
protect both liver types against I/R injury. Our results showed a
potential relationship between IGF-I and EGF in both liver types
under warm ischemic conditions. In contrast with the results
obtained in different types of cells (12–14), EGF did not enhance
igf1 expression in our conditions. The results reported here in-
dicate that IGF-I induces egf expression in both steatotic and
nonsteatotic livers under hepatic I/R conditions. Previous studies
from our group revealed the key role of both p38 and PPAR in
nonsteatotic and steatotic livers, respectively, under I/R condi-
tions (16, 17), and data reported in the literature have indicated
that IGF-I and EGF affect p38 and PPAR in several different
conditions (18–21). In the present study,wehypothesize that the
benefits of EGF on hepatic I/R injury could be explained, at least
partially, by a reduction in p38 activation in nonsteatotic livers
and by overexpression of PPAR in the presence of steatosis.
Thus, EGFprotectedboth liver types, possibly bydifferentmech-
anisms. This is in line with reports indicating that the multiple
intracellular signaling induced by EGF depends on cell type.
Moreover, the EGF signaling pathway in the same cell type may
result in completely different effects dependingonnumerous fac-
tors including the concentration of growth factor, the number
of receptors displayed on the cell surface, and docking and
target proteins and their initial activity state (54–56). Taking
these observations into account, and the structural and func-
tional differences between hepatocytes with or without fatty
infiltration (57–59), it is not surprising that our results show
a differential effect of EGF on p38 and PPAR, depending on
the type of liver.
In conclusion, pharmacological strategies based on IGF-I and
EGF administration could open new pathways for protecting
steatotic livers against I/R, although they do not need to be ad-
ministered in combination. Moreover, EGF administration
could be a more appropriate clinical therapy because EGF pro-
tected both liver types at the same dose and its effects are more
direct than IGF-I. Finally, EGF protected the liver against I/R
injury by reducing p38 activation in nonsteatotic livers and in-
ducing PPAR overexpression in steatotic livers.
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